4C Medical Technologies

The First Mitral Regurgitation Therapy that Preserves the Native Mitral Valve

Learn more
4C Medical Technologies

Mitral Regurgitation

Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 percent of Americans aged ≥75 years. MR occurs when the mitral valve leaflets do not close properly and allow blood in the left ventricle to leak back into the left atrium. It is a progressive disease and if left untreated, MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and death.

Learn more

Latest News

4C Medical Technologies Announces $17 Million Series A Financing
15-Sep-2018

MINNEAPOLIS, MN, September 10, 2018 – 4C Medical Technologies, Inc. (4C Medical), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, t..

Read more
4C Medical’s AltaValve First In Human Experience to be Presented at TCT 2018
15-Sep-2018

Brooklyn Park, Minn. – September 13, 2018 – 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a trans..

Read more
4C Medical Advances the State of the Heart
29-Jun-2018

4C Medical Technologies, Inc. (4C Medical), named after the four chambers of the heart, is developing a novel, minimally invasive device for the treatment of mitral regurgitation (MR). MR impacts up to 10 percen..

Read more